ReviewAntibiotics (Basel, Switzerland)2021
Antimicrobial Resistance in Common Respiratory Pathogens of Chronic Bronchiectasis Patients: A Literature Review.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Epidemiology, risk factors and clinical outcomes of multidrug-resistantJournal of thoracic disease · 2026Article
- Integrated traditional Chinese medicine and Western medicine strategies for the treatment of bronchiectasis: a comprehensive review.Chinese medicine · 2026Review
- Risk factors and prediction model for chronic bacterial infection in stable bronchiectasis in Shanghai, China.Frontiers in medicine · 2026Article
- Data-driven strategies for drug repurposing: insights, recommendations, and case studies.Briefings in bioinformatics · 2025Article
- Potential Microorganisms from Bronchial Lavage Fluid in Bronchiectasis Patients: Bacteria, Nontuberculous Mycobacteria, and Fungi.The open respiratory medicine journal · 2025Article
- Factors Associated With Multi-Drug Resistant Organisms Among Bronchiectasis Patients: A Retrospective Study of Bronchiectasis Patients in Jordan.International journal of general medicine · 2025Article
- The role of T-helper and T regulatory cells in driving neutrophilic and eosinophilic inflammation in bronchiectasis.Frontiers in immunology · 2025Review
- Athletic protocol in non-cystic fibrosis-related bronchiectasis: rationale and design of the pilot ATHOS study.Frontiers in medicine · 2025Article
- Review
- Epidemiology and outcomes of multidrug-resistant bacterial infection in non-cystic fibrosis bronchiectasis.Annals of clinical microbiology and antimicrobials · 2024Article
- Respiratory infectious burden in a cohort of antibody deficiency patients treated with immunoglobulin replacement therapy: The impact of lung pathology and gastroesophageal reflux disease.The journal of allergy and clinical immunology. Global · 2023Article
- Fast Track Diagnostic Tools for Clinical Management of Sepsis: Paradigm Shift from Conventional to Advanced Methods.Diagnostics (Basel, Switzerland) · 2023Review
- Microbiology sampling in non-cystic fibrosis bronchiectasis cases from northern Alberta.PloS one · 2023Article
- Antibiotic Tolerance Indicative of Persistence Is Pervasive among Clinical Streptococcus pneumoniae Isolates and Shows Strong Condition Dependence.Microbiology spectrum · 2022Article
- Sputum antimicrobial susceptibility patterns and clinical outcomes among adult Aboriginal Australians with bronchiectasis.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-cystic fibrosis bronchiectasis is a chronic disorder in which immune system dysregulation and impaired airway clearance cause mucus accumulation and consequent increased susceptibility to lung infections. The presence of pathogens in the lower respiratory tract causes a vicious circle resulting in impaired mucociliary function, bronchial inflammation, and progressive lung injury. In current guidelines, antibiotic therapy has a key role in bronchiectasis management to treat acute exacerbations and chronic infection and to eradicate bacterial colonization. Contrastingly, antimicrobial resistance, with the risk of multidrug-resistant pathogen development, causes nowadays great concern. The aim of this literature review was to assess the role of antibiotic therapy in bronchiectasis patient management and possible concerns regarding antimicrobial resistance based on current evidence. The authors of this review stress the need to expand research regarding bronchiectasis with the aim to assess measures to reduce the rate of antimicrobial resistance worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.